TIDMABC

RNS Number : 0360M

ABCAM Plc

01 May 2015

 
 For immediate release   1 May 2015

ABCAM PLC

("Abcam" or "the Company")

Total Voting Rights - Voting Rights and Capital

In conformity with 5.6.1 of the Disclosure and Transparency Rules, the Company notifies the market of the following:

The Company's issued share capital consists of 201,018,956 Ordinary Shares of 0.2p each with voting rights. The Company does not hold any shares in Treasury.

The above figure of 201,018,956 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules.

Date of Notification: 1 May 2015

For further information please contact:

 
                                                        + 44 (0) 1223 
Abcam                                                         696 000 
Jeff Iliffe, Chief Financial Officer 
 Laura Taylor, Investor Relations Manager 
 
J.P.Morgan Cazenove - Nominated Adviser & Joint      + 44 (0) 20 7742 
 Corporate Broker                                                4000 
James Mitford / Alex Bruce - Nominated Adviser 
 
                                                     + 44 (0) 20 7418 
Peel Hunt LLP - Joint Corporate Broker                           8900 
Clare Terlouw / Jock Maxwell MacDonald - Corporate 
 Broking

Notes to Editors

About Abcam

Abcam plc is a global leader in the supply of life science research tools, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.

Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.

Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices enabling local services and multi-language support and sells to over 100 countries. The Company was founded in 1998, and now employs over 800 people. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVRUGUQCAUPAGGG

Abcam (LSE:ABC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Abcam Charts.
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Abcam Charts.